- Highlights
• In acute isolated SVT, the prevalence of cancer is almost 7 %.
• Cancer increases the SVT-associated VTE risk at 3 and 12 months.
• Cancer patients with isolated SVT may benefit from prolonged anticoagulation.
Abstract
Background: Despite significant progress in the understanding of paraneoplastic deep vein thrombosis (DVT) and pulmonary embolism (PE), little is known about the outcomes of cancer-associated superficial vein thrombosis (SVT) in daily practice.
Methods: INSIGHTS-SVT was a prospective observational study on patients with acute isolated SVT. Primary outcome measure was symptomatic venous thromboembolism (VTE), a composite of DVT, PE, and SVT extension/recurrence, at 3 months. Clinically relevant bleeding was also assessed.
Results: Of 1151 patients included, 6.7 % either had active cancer at baseline or were diagnosed with cancer during 12 months of follow-up. At 3 months, symptomatic VTE had occurred in 13.0 % and 5.4 % of cancer and non-cancer patients, respectively (HR 2.6, 95 % CI 1.3–5.0). Regarding secondary outcomes, cancer patients had increased risks of DVT and PE (HR 3.9, 95 % CI 1.3–11.8) and hospitalization due to VTE (HR 11.0, 95 % CI 2.5–49.0). The rate of clinically relevant bleeding was numerically higher in the cancer cohort (3.9 % vs 1.3 %, HR 3.1, 95 % CI 0.9–10.7). At 12 months, the primary composite outcome had occurred in 15.6 % and 11.9 % of cancer and non-cancer patients, respectively (HR 1.9, 95 % CI 1.0–3.5). After adjusting for additional risk factors, including age, history of DVT/PE and cardiovascular risk factors/diseases, the association of cancer with the primary outcome remained statistically significant.
Conclusion: Cancer patients with isolated SVT are at significant risk of symptomatic VTE. While most events occur within 3 months, the VTE risk remains elevated up to one year of follow-up.
ClinicalTrials.gov identifier: NCT02699151.
MetadatenAuthor: | Florian LangerGND, Horst E. Gerlach, Alexandra Schimke, Andreas HeinkenORCiD, Ulrich Hoffmann, Thomas NoppeneyORCiDGND, David PittrowORCiDGND, Jens KlotscheORCiDGND, Eberhard RabeORCiDGND, Rupert BauersachsORCiDGND |
---|
URN: | urn:nbn:de:hebis:30:3-786201 |
---|
DOI: | https://doi.org/10.1016/j.thromres.2022.10.022 |
---|
ISSN: | 0049-3848 |
---|
Pubmed Id: | https://pubmed.ncbi.nlm.nih.gov/36370650 |
---|
Parent Title (English): | Thrombosis research |
---|
Publisher: | Elsevier |
---|
Place of publication: | Amsterdam [u.a.] |
---|
Document Type: | Article |
---|
Language: | English |
---|
Date of Publication (online): | 2022/11/09 |
---|
Date of first Publication: | 2022/11/05 |
---|
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Creating Corporation: | INSIGHTS-SVT study group |
---|
Release Date: | 2024/03/21 |
---|
Tag: | Cancer; Fondaparinux; Low-molecular-weight heparin; Malignancy; Observational; Risk assessment; Superficial vein thrombosis; Treatment; Venous thrombosis |
---|
Volume: | 220 |
---|
Page Number: | 8 |
---|
First Page: | 145 |
---|
Last Page: | 152 |
---|
HeBIS-PPN: | 520379926 |
---|
Institutes: | Medizin |
---|
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Licence (German): | Creative Commons - Namensnennung-Nicht kommerziell - Keine Bearbeitung 4.0 |
---|